FDA Approves Tremfya (guselkumab) for the Treatment of Pediatric Plaque Psoriasis and Active Psoriatic Arthritis
Drugs.com,
HORSHAM, PA, (September 29, 2025) – Johnson
U.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor
BioSpace,
TREMFYA® is now approved for pediatric patients living with moderate to severe plaque psoriasis, who are candidates for…
PSORIASIS U.S. FDA Approves TREMFYA® (uselkumab) for the Treatment of Pediatric Plaque Psoriasis and Active Psoriatic Arthritis
Pharma's Almanac,
TREMFYA® is now approved for pediatric patients living with moderate to severe plaque psoriasis, who are candidates for…
U.S. FDA approves TREMFYA(TM) (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor
Stockwatch,
PR Newswire HORSHAM, Pa., Sept. 29, 2025 TREMFYA® is now approved for pediatric patients living with moderate to severe plaque…